| Literature DB >> 36038925 |
Annemieke K van den Broek1, Jara R de la Court2,3, Thomas Groot4, Reinier M van Hest5, Caroline E Visser4, Kim C E Sigaloff1, Rogier P Schade4, Jan M Prins1.
Abstract
OBJECTIVES: Evaluation of the appropriateness of the duration of antimicrobial treatment is a cornerstone of antibiotic stewardship programs, but it is time-consuming. Furthermore, it is often restricted to antibiotics prescribed during hospital admission. This study aimed to determine whether mandatory prescription-indication registration at the moment of prescribing antibiotics enables reliable automated assessment of the duration of antibiotic therapy, including post-discharge duration, limiting the need for manual chart review to data validation.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36038925 PMCID: PMC9426230 DOI: 10.1186/s13756-022-01147-2
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 6.454
Fig. 1Defining the total antibiotic therapy duration for the definitive registered indication
Fig. 2Overview of the data selection steps resulting in the final dataset. *Exclusion criteria may overlap
Accuracy of extracted duration and selected indications
| Duration of therapy | Indication of therapy | |
|---|---|---|
| Error rate location AMC (%) | 10/200 = 5.0% 6 prescriptions not electronically prescribed (all were OPAT prescriptions) 1 prescription of which start fell before inclusion paeriod and therefore not included in the dataset 1 missing non-J01 antibiotic (oral metronidazole) 2 prescriptions were not terminated after discharge or death | 31/200 = 15.5% Incorrectly registered indications affecting duration of therapy: 12/31 = 38.7%a |
| Error rate location VUMC (%) | 8/200 = 4.0% 8 prescriptions not electronically prescribed (of which 5 were OPAT prescriptions) | 37/200 = 18.5% Incorrectly registered indications affecting duration of therapy: 23/37 = 62.0%c |
| Total | 18/400 = 4.5% | 68/400 = 17.0% Incorrectly registered indications affecting duration of therapy: 35/400 = 8.8% |
OPAT Outpatient parenteral antimicrobial therapy
Length of treatment (LOT) per indication
| Definitive diagnosis | Total (n) | Treatment courses with post-discharge treatment (n;%) | Percentage of total treatment duration given post-discharge (%;SD)* | LOT in days, | Recommended course duration** | Guideline adherence*** | Treatment courses too long (%) |
|---|---|---|---|---|---|---|---|
| UTI—Cystitis | 420 | 231 (55) | 63 (21) | 6.5 (4.0–10.0) | 3–7 days | 53 | 31 |
| UTI—Complicated UTI | 241 | 164 (68) | 63 (18) | 12.0 (7.0–15.0) | 7–14 days | 60 | 15 |
| UTI—CAD | 28 | 15 (54) | 65 (18) | 11.0 (4.8–14.0) | 7–14 days | 57 | 14 |
| UTI—Kidney transplant | 47 | 28 (60) | 59 (17) | 11.0 (5.5–15.0) | |||
| UTI—Other (not specified) | 89 | 60 (67) | 68 (18) | 13.0 (7.0–15.0 | |||
| RTI—CAP-m | 328 | 142 (43) | 54 (20) | 6.0 (5.0–8.0) | 5 days | 35 | 40 |
| RTI—CAP-s | 90 | 17 (19) | 46 (24) | 5.0 (3.0–7.0) | 5 days | 29 | 31 |
| RTI—HAP | 41 | 6 (15) | 37 (24) | 6.0 (4.0–8.0) | 5–7 days | 46 | 24 |
| RTI—Aspiration | 82 | 23 (28) | 51 (20) | 6.5 (5.0–9.0) | 5 days | 26 | 50 |
| RTI—COPD | 73 | 32 (44) | 58 (18) | 6.0 (3.0–8.0) | 7 days | 38 | 14 |
| RTI—Abscess/empyema | 23 | 9 (39) | 55 (19) | 8.0 (5.5–15.0) | |||
| RTI—Other (not specified) | 154 | 51 (33) | 56 (17) | 6.0 (3.0–8.8) | |||
| CNS infection | 51 | 7 (14) | 70 (21) | 8.0 (3.0–11.5) | |||
| CVL infection | 29 | 11 (38) | 59 (17) | 7.0 (4.0–13.0) | |||
| ENT infection | 106 | 88 (83) | 63 (14) | 10.0 (9.0–13.0) | 7–14 days | 75 | 10 |
| Gastro-enteritis | 40 | 14 (35) | 60 (21) | 5.0 (3.0–8.0) | |||
| Gynaecological infection | 165 | 91 (55) | 68 (16) | 7.0 (2.0–11.0) | |||
| Intra-abdominal infection | 464 | 145 (31) | 52 (19) | 6.0 (4.0–8.0) | |||
| Sepsis e.c.i./unkown | 270 | 53 (20) | 56 (20) | 4.0 (3.0–7.0) | |||
| Skin or soft tissue infection | 336 | 214 (64) | 62 (19) | 11.0 (7.0–15.0) | 10–14 days | 44 | 16 |
| Other (not specified) | 157 | 49 (31) | 63 (19) | 6.0 (3.0–10.0) | |||
| Total | 3390 | 1502 (44) | 60 (19) | 7.0 (4.0–11.0) | |||
| Excluded**** | 232 |
*Proportions are only given for treatment courses with post-discharge treatment
**Recommended by Dutch guidelines (www.swabid.nl)
*** One additional day was allowed as each calendar day on which a dose was given was counted as a full day of treatment
**** Indications that were rarely selected, i.e. in less than 20 treatment courses, or that would require > 21 days of treatment according to our national guidelines were excluded. These included the following indications: Bone and Joint infection, S. aureus bacteraemia, Endovascular infection, Eye infection, Febrile neutropenia, Fungal infection, Mediastinitis, UTI–cyst infection and chronic prostatatitis
SD Standard deviation, UTI Urinary tract infection, UTI-CAD Catheter-associated urinary tract infection, RTI Respiratory tract infection, CAP-m Community-acquired pneumonia mild-to-moderate severe, CAP-s Community-acquired pneumonia severe, HAP Hospital-acquired pneumonia, COPD Chronic obstructive pulmonary disease, CNS Central nervous system, CVL Central venous line